DXCM Stock Analysis — Dexcom
Sector: Healthcare
AI Verdict
Dexcom trades at 26.1x next year's earnings with 38.2% expected EPS growth—cheap for this level of growth if its sensor ecosystem keeps competitors at bay, but the sky-high RSI means a sharp pullback is likely in the near term.
Competitive Moat
Dexcom dominates continuous glucose monitoring (CGM) for diabetics, with proprietary sensor technology and deep integration into digital health platforms that create high switching costs for patients and providers. Its vast patient data network and FDA-cleared algorithms make it hard for new entrants to match accuracy and regulatory trust.
Summary
Dexcom's stock is in the spotlight due to a 38.2% forward EPS growth forecast and an RSI of 82.4, signaling extreme overbought conditions.
Where It Stands
The stock is up 13.56% over the past year, trades at 26.1x next year's earnings versus the healthcare sector median of 22x, and its RSI of 82.4 is deep into overbought territory.
Key Metrics
- RSI: 82.4 — Overbought
- Trailing P/E: 36.0x
- Forward P/E: 26.1x
- PEG Ratio: 0.98
- Earnings Growth: +0.4%
- Revenue Growth: +0.2%
- Market Cap: $34.3B
- 1-Year Return: 13.56%
- 52-Week High: $91.04
- 52-Week Low: $54.11
Analyst Consensus
31 Buy · 5 Hold · 0 Sell (36 analysts)
Bull Case
With analysts expecting 38.2% EPS growth and a forward P/E of 26.1x, you're paying a fair multiple for rapid earnings acceleration if Dexcom's CGM moat holds.
Bear Case
If the forward P/E compresses from 26.1x to the sector median of 22x, the stock could drop roughly 16%, and the RSI of 82.4 suggests a technical pullback is overdue.
Catalyst to Watch
Watch for upcoming FDA approvals or Medicare reimbursement changes, as either could materially shift growth expectations.